Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS

Nail psoriasis (NP) has been proposed as a potential clinical predictor for a more severe disease course in children with psoriasis but data regarding NP in children is scarce. Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-(IL)-17A, is an EMA and FDA approved treatment for pediatric (≥6 years old) and adult patients with moderate-to-severe psoriasis and provides rapid clinically meaningful improvements in skin, itch and quality of life (QoL) outcomes at week 12.